NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
Ocumetics Corporate Update and FIH Study Progress FAQ
Ocumetics Technology Corp. reports positive six-month results from its First-in-Human study, advancing to Group Two surgeries, and launches a financing initiative to fund clinical development and commercialization efforts.
Ocumetics announced positive six-month results from its First-in-Human (FIH) study, which supports advancement to Group Two clinical surgeries, and provided updates on manufacturing, regulatory, financing, and commercialization activities.
The positive six-month data allow the Company to proceed to Group Two surgeries, marking an important milestone in the clinical development of the Ocumetics Lens towards commercialization.
Group Two surgeries remain on track for Q3 2026 in Mexico City.
The financing initiative aims to fund completion of the FIH study, including Group Two surgeries, manufacturing, sterilization, regulatory programs, and strategic partnerships.
Ocumetics is in discussions with four of the world's seven largest ophthalmic companies regarding future partnership and commercialization opportunities.
Manufacturing of the redesigned Ocumetics Lens has commenced in Germany in preparation for Group Two surgeries.
All regulatory requirements necessary to proceed to Group Two surgeries have been successfully completed.
The redesigned lens incorporates significant advancements in manufacturability, surgical performance, and scalability.
Ocumetics conducted more than 50 one-on-one meetings with institutional investors, family offices, high-net-worth investors, and strategic industry participants.
Dean Burns is the President and Chief Executive Officer of Ocumetics Technology Corp.